why choose us

Clinical Trials Search

Showing 8,290 of 132,656 result(s)
Live Instruction and Fitness Tracking*: A 12-week Combined Aerobic and Resistance Training Intervention

Status: COMPLETED

Condition: Physical Inactivity

Interventions: A 12-week combined aerobic and resistance training exercise protocol

Date: 2023-09-19

A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules

Status: NOT_YET_RECRUITING

Condition: Pulmonary Nodule

Interventions: Undergo blood draw

Date: 2023-09-19

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Status: Completed

Condition: Peripheral T Cell Lymphoma

Interventions: Belinostat 600 mg;m2 or 1000 mg;m2 along with CHOP is given in each cycle

Date: 2023-09-19

Somatic Mosaicism in Twins Discordant for Childhood Cancer

Status: Completed

Condition: Pediatric Central Nervous System Tumor

Interventions: Collection of both blood and saliva samples from participants at the time of study enrollment

Date: 2023-09-19

Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude

Status: COMPLETED

Condition: High Altitude

Interventions: Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days

Date: 2023-09-19

Prevalence of Pain in Hospitalized Cirrhotic Patients

Status: Completed

Condition: Cirrhosis

Interventions: All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have p

Date: 2023-09-19

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Status: COMPLETED

Condition: Solid Tumor, KRAS Mutation

Interventions: BI 3706674

Date: 2023-09-19

A Study to Evaluate the Efficacy and Safety of AD-223

Status: COMPLETED

Condition: Hypertension,Essential

Interventions: PO, Once daily(QD), 8weeks

Date: 2023-09-19

CX3CR1+T Cell Predict Immunotherapy Efficacy

Status: COMPLETED

Condition: Non-small Cell Lung Cancer

Interventions: Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy.
PD-1 drug selection should be limited in 4

Date: 2023-09-19

CX3CR1+T Cell Predict Immunotherapy Efficacy

Status: COMPLETED

Condition: Non-small Cell Lung Cancer

Interventions: Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy.
PD-1 drug selection should be limited in 4

Date: 2023-09-19